<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543916</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-17-13842</org_study_id>
    <secondary_id>HM20019851</secondary_id>
    <nct_id>NCT04543916</nct_id>
  </id_info>
  <brief_title>Venetoclax and Irinotecan in Relapsed/Refractory SCLC</brief_title>
  <official_title>A Phase 1/2 Study of Venetoclax and Irinotecan in Relapsed/Refractory Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-arm, open-label, multicenter phase 1/2 trial designed to establish the&#xD;
      recommended phase 2 dose (RP2D) of daily oral venetoclax when given in combination with&#xD;
      irinotecan in patients with relapsed or refractory small cell lung cancer (SCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irinotecan will be given at 60 mg/m2 on days 1, 8, and 15 of each 28-day cycle. A 3+3 dose&#xD;
      escalation design will be followed until the maximum tolerated dose (MTD) of venetoclax has&#xD;
      been determined. Once the MTD is established, a RP2D that is the same as or less than the MTD&#xD;
      will be determined. If no RP2D can be determined, the study will close to accrual. The RP2D&#xD;
      will be used in an expansion cohort based on a Simon's two-stage minimax design to evaluate&#xD;
      efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    AbbVie decided to stop trial involving Venetoclax for safety measures needed&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2028</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation will proceed within each cohort. Phase II is the expansion cohort at the recommended phase 2 dose found in phase 1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Determine the recommended phase 2 dose (RP2D) of venetoclax with irinotecan in patients with relapsed or refractory SCLC</measure>
    <time_frame>90 Days</time_frame>
    <description>Recommended phase 2 dose (RP2D) of venetoclax in combination with irinotecan that is less than or equal to the maximum tolerated dose (MTD). A 3+3 dose escalation design will be followed until the maximum tolerated dose (MTD) of venetoclax has been determined. Patients assigned to a dose level of venetoclax greater than 50 mg will undergo a ramp-up phase during the first week of irinotecan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Evaluate the efficacy of venetoclax with irinotecan in patients with relapsed or refractory SCLC</measure>
    <time_frame>180 Days</time_frame>
    <description>The RP2D will be used in an expansion cohort based on a Simon's two-stage minimax design to evaluate efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the frequency of adverse events (AEs)</measure>
    <time_frame>120 Days</time_frame>
    <description>Assess adverse events (AEs) characterized and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE V 5.0) to determine safety and toxicity of the combination of venetoclax and irinotecan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the antitumor effects of venetoclax and irinotecan in combination.</measure>
    <time_frame>180 Days</time_frame>
    <description>Evaluate the anti tumor effects of tumor response based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observe survival in relapsed or refractory SCLC patients receiving venetoclax in combination with irinotecan</measure>
    <time_frame>180 Days</time_frame>
    <description>Progression-free survival and overall survival of patients with relapsed or refractory SCLC receiving venetoclax in combination with irinotecan</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsed Small Cell Lung Cancer</condition>
  <condition>Refractory Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 50mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 100mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 200mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 400mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 600mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax recommended phase 2 dose (RP2D) by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 50 MG</intervention_name>
    <description>Escalating doses to determine recommended phase 2 dose (RP2D)</description>
    <arm_group_label>Dose Level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 100 MG</intervention_name>
    <description>Escalating doses to determine recommended phase 2 dose (RP2D)</description>
    <arm_group_label>Dose Level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 200 MG</intervention_name>
    <description>Escalating doses to determine recommended phase 2 dose (RP2D)</description>
    <arm_group_label>Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 400</intervention_name>
    <description>Escalating doses to determine recommended phase 2 dose (RP2D)</description>
    <arm_group_label>Dose Level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 600</intervention_name>
    <description>Escalating doses to determine recommended phase 2 dose (RP2D)</description>
    <arm_group_label>Dose Level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan 60 mg/m2</intervention_name>
    <description>Intravenously (IV), days 1, 8, and 15</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_label>Phase 2 Expansion Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax (RP2D)</intervention_name>
    <description>orally, once per day</description>
    <arm_group_label>Phase 2 Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological diagnosis of SCLC&#xD;
&#xD;
          -  Disease progression or recurrence during or after platinum-based therapy, unless&#xD;
             platinum-based therapy was contraindicated&#xD;
&#xD;
          -  Phase 1: Measurable or evaluable disease according to RECIST v1.1&#xD;
&#xD;
          -  Phase 2: Measurable disease according to RECIST v1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Adequate bone marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Adequate renal function as defined below:&#xD;
&#xD;
          -  Serum creatinine ≤ upper limit of normal (ULN) for the lab or a calculated creatinine&#xD;
             clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Adequate hepatic function as defined below:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN for the laboratory&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤ 2.5 x ULN for the laboratory&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) ≤ 2.5 x ULN for the laboratory&#xD;
&#xD;
          -  Persons with known HIV seropositivity are eligible if they meet the following&#xD;
             criteria:&#xD;
&#xD;
               -  CD4 count ≥ 200/mm3&#xD;
&#xD;
               -  Undetectable HIV viral load on standard PCR-based test&#xD;
&#xD;
               -  On a stable regimen of highly active anti-retroviral therapy (HAART) that does&#xD;
                  not include protocol contraindicated agents&#xD;
&#xD;
               -  No ongoing requirement for concurrent antibiotics or antifungal agents for the&#xD;
                  prevention of HIV-associated opportunistic infections&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing requirement for any non-study anticancer therapy&#xD;
&#xD;
          -  Ongoing or planned treatment with any of the following:&#xD;
&#xD;
               -  Greater than 10 mg prednisone daily or equivalent&#xD;
&#xD;
               -  Immunosuppressive agents&#xD;
&#xD;
               -  Strong or moderate CYP3A inhibitor or inducer, or a narrow-therapeutic sensitive&#xD;
                  substrate&#xD;
&#xD;
               -  P-gp inhibitor or narrow-therapeutic sensitive P-gp substrate If any of these&#xD;
                  agents have been used, patients must be off them for ≥ 1 week before initiation&#xD;
                  of study treatment.&#xD;
&#xD;
          -  Any investigational agent within 21 days prior to the first dose of the&#xD;
             investigational drugs&#xD;
&#xD;
          -  Has consumed grapefruit, grapefruit products, Seville oranges, or starfruit within 3&#xD;
             days before initiation of study treatment.&#xD;
&#xD;
          -  Phase 2 portion only: Previous systemic anticancer therapy other than platinum-based&#xD;
             therapy&#xD;
&#xD;
          -  Known leptomeningeal metastases&#xD;
&#xD;
          -  Known untreated brain metastases&#xD;
&#xD;
          -  Hypersensitivity to irinotecan, venetoclax, or their excipients&#xD;
&#xD;
          -  Diarrhea ≥ grade 1&#xD;
&#xD;
          -  Ongoing need for antidiarrheal agents&#xD;
&#xD;
          -  Active uncontrolled infection, ongoing or within 2 weeks before initiating treatment&#xD;
&#xD;
          -  Known homozygosity for the UGT1A1*28 allele Note: Study-specific UGT1A1 testing is not&#xD;
             required&#xD;
&#xD;
          -  Inability to swallow oral medications and/or malabsorption&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Medical, psychological, or social condition that, in the opinion of the investigator,&#xD;
             may increase the patient's risk or limit the patient's adherence with study&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sosipatros Boikos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed SCLC</keyword>
  <keyword>Refractory SCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

